| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0006699 | Bile acid biosynthetic process | Increases phenotype | PMID:29128616 |
| GO:0006750 | Glutathione biosynthetic process | Increases phenotype | PMID:29128616 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:34822940 |
| GO:0007005 | Mitochondrion organization | Affects phenotype | PMID:34822940 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:37364641 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:29128616 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:35739755 |
| GO:0010906 | Regulation of glucose metabolic process | Affects phenotype | PMID:35739755; PMID:37364641 |
| GO:0033327 | Leydig cell differentiation | Decreases phenotype | PMID:33075588 |
| GO:0034599 | Cellular response to oxidative stress | Increases phenotype | PMID:33052911 |
| GO:0035360 | Positive regulation of peroxisome proliferator activated receptor signaling pathway | Increases phenotype | PMID:26519955 |
| GO:0042632 | Cholesterol homeostasis | Decreases phenotype | PMID:35739755 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:35739755; PMID:37364641 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:34822940 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:34822940 |
| GO:0046881 | Positive regulation of follicle-stimulating hormone secretion | Increases phenotype | PMID:37364641 |
| GO:0050890 | Cognition | Decreases phenotype | PMID:32716663 |
| GO:0070328 | Triglyceride homeostasis | Decreases phenotype | PMID:35739755 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:34822940 |
| GO:0072520 | Seminiferous tubule development | Affects phenotype | PMID:37364641 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:34822940 |
| GO:0140354 | Lipid import into cell | Increases phenotype | PMID:35739755 |
| GO:0160024 | Leydig cell proliferation | Decreases phenotype | PMID:33075588 |
| GO:1902884 | Positive regulation of response to oxidative stress | Increases phenotype | PMID:35739755 |
| GO:1904598 | Positive regulation of connective tissue replacement involved in inflammatory response wound healing | Increases phenotype | PMID:35739755 |
| GO:2000180 | Negative regulation of androgen biosynthetic process | Increases phenotype | PMID:33075588 |
| GO:2000844 | Negative regulation of testosterone secretion | Increases phenotype | PMID:33075588 |
| GO:2000845 | Positive regulation of testosterone secretion | Increases phenotype | PMID:37364641 |
| GO:2000866 | Positive regulation of estradiol secretion | Increases phenotype | PMID:37364641 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.